natgillin/translations-raw huggingface dataset:
to 10 mg of the peptide having the amino acid sequence of SEQ ID NO: 2, preferably 0.1, 0.5 or 1 mg of the peptide; and to 0.5 mg of an adjuvant, preferably human granulocyte macrophage-colony stimulating factor (GM-CSF), wherein the composition is formulated for intradermal injection. 
(i)_0.1 mg do 10 mg peptida, poželjno 0.1. 0.5 ili 1 mg peptida; te (1i) kao adjuvant 0.01 do 0.5 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF), a poželjno 0.25 ili 0.125 mg GM-CSF.
Values of this order are also applicable, as particularly preferred values, to the atomiser 11 according to the teaching of the present invention. 
Vrijednosti ovih veličina mogu se također aplicirati kao vrijednosti kojima se daje posebnu prednost za atomizer 11 prema pouci predloženog izuma,
A pharmaceutical composition comprising as active ing redient a compound according to any one of Claims 1-4, optionally together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema zahtjevu 1 kao aktivni sastojak, opcijski zajedno sa farmaceutski prihvatljivim razrjeđivačem ili nosačem.
The boom mountable robotic arm of claim 1 wherein said electrically insulated support post includes an insulated upright portion and a riser portion, said riser portion having a first end pivotably connected to said upper beam assembly and a second end supporting said insulated upright portion, and wherein an actuator angularly extends from said second end of said riser portion to said upper beam assembly. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 1, naznačena time, da navedeni električno izolirani podupirač uključuje izolirani uspravni dio 1 podizni dio, gdje navedeni podizni dio ima prvi kraj stožerno spojen na navedeni gornji gredni sklop te drugi kraj koji pridržava navedeni izolirani uspravni dio, te se pritom aktivator proteže pod kutom iz navedenog drugog kraja od navedenog podiznog dijela prema navedenom gornjem grednom sklopu.
The product was filtered and dried in vacuum (30-50 mbar) at a temperature of 30-35°C. The drying was controlled by measuring the water content (Karl Fischer not more than 4.5 %). 
HR P20090104 T3 filtriran i osušen u vakuumu (30-50 mbara) na temperaturi od 30-35 C. Sušenje je bilo kontrolirano mjerenjem sadržaja vode (ne više od 4,5 %, određeno Karl Fischerovom metodom).
The combination of Claim 8, wherein the B-lactamase inhibitor is in the form of a sodium or calcium salt. 
Kombinacija sukladno patentnom zahtjevu 8, naznačena time što je B-laktamazni inhibitor u obliku natrijeve ili kalcijeve soli.
A method for preparing the pharmaceutical composition of any one of claims 1∼8, characterized in that the method comprising following steps: preparation of #1 Extract: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis and Semen Cassiae are mixed, extracted by using heating refluxing with ethanol, and filtered to remove impurities; and the ethanol is recovered and concentrated to give #1 Extract for later use; preparation of #2 Extract: Radix Paeoniae alba is extracted by using heating refluxing with ethanol, and filtered; and the ethanol is recovered and concentrated to give #2 Extract for later use; 
Postupak za pripravu farmaceutskog pripravka za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da postupak obuhvaća slijedeće korake: a). Priprema ekstrakta br. 1: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis i Semen Cassiae se pomiješaju, ekstrahiraju uz refluks i zagrijavanje s etanolom i filtriraju kako bi se uklonile nečistoće; i etanol se izdvaja i koncentrira kako bi se dobio ekstrakt br. 1 za kasniju uporabu; b). priprema ekstrakta br. 2: Radix Paeoniae alba se ekstrahira uz refluks i zagrijavanje s etanolom i filtrira; i etanol se izdvaja i koncentrira kako bi se dobio ekstrakt br. 2 za kasniju uporabu;
The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition. 
Odjeljci koji slijede pružaju definicije različitih kemijskih tvari koje čine spojeve u skladu s izumom i s namjerom da se podjednako primjenjuju unutar specifikacije i patentnih zahtjeva osim ako izričito iznesena definicija ne pruža šire određenje.
The method according to claim 14, wherein the reading the mutual position relationship between the respective touch points and the authenticating whether the plurality of touch points are the touch points of the valid touch device includes authenticating whether a polygonal geometric characteristic formed by segments connecting the respective touch points includes a polygonal geometric characteristic capable of being formed by connecting center points of the touch portions arranged in the touch device. 
Metoda u skladu s zahtjevom 6, naznačena time što korak provjere autentičnosti točke dodira uključuje autentifikaciju uključuje li poligonalna geometrijska karakteristika formirana segmentima koji povezuju dotične točke dodira poligonalnu geometrijsku karakteristiku koja može biti formirana povezivanjem središnjih točaka dodirnih dijelova (300) raspoređenih u dodirnom uređaju.
The modified LCAT protein of any one of claims 1-5 for decreasing accumulation of cholesterol in a subject. 
Modificirani LCAT protein prema patentnom zahtjevu 15 za uporabu u postupku za liječenje ili prevenciju kardiovaskularne bolesti.
conducting the search for the target record comprising both said secret keycode (109a) and said presenter identifier (108a); 
(e) provođenja potrage za ciljanom bilješkom koja sadrži i navedeni tajni kodni ključ (109) i navedeni identifikator prikazivača (108a);
The above-mentioned fatty alcohol is preferably selected from the group consisting of lauryl alcohol, stearyl alcohol, myristyl alcohol, arachidyl alcohol, behenyl alcohol and cetylstearyl alcohol, the latter (Cetearyl Alcohol) being particularly preferred. 
Formulacija prema patentnom zahtjevu 1, naznačen time što je navedeni masni alkohol izabran iz grupe koja se sastoji od lauril alkohola, stearil alkohola, miristil alkohola, arahidil alkohola, behenil alkohola 1 cetilstearil alkohola i poželjno je cetilstearil alkohol (cetearil alkohol).
the solvent for the oxidation process is water and 
- otapalo za postupak oksidacije je voda i
The method according to claims 1-5, characterized in that the transesterification is carried out at a temperature in the range of 80 to 130°C. 
Postupak u skladu s patentnim zahtjevima 1-5, naznačen time, da trans-esterifikacija izvodi pri temperaturi u rasponu od 80 do 130°C.
and/or pharmaceutically-acceptable salts, prodrugs, solvates, stereoisomer, and/or hydrates thereof. 
Loza 6 dom ili njihovih farmaceutski prihvatljivih soli i/ili stereoizomera, 6.
The isolated fusion protein of clause 7, wherein human Fc polypeptide is a human IgM polypeptide or a human IgG Fc polypeptide. 
Izolirani fuzijski protein za uporabu prema patentnom zahtjevu 1, naznačen time, što je bolest ili poremećaj nedostatak AAT.
represents a C1 to C6 alkyl group, the alkyl group optionally being substituted by a methylthio or benzyloxy group, a phenyl group, a phenyl-C1-4 alkyl group, or an indolyl-C1-4 alkyl group, the phenyl group or the indolyl group optionally being substituted by a C1 to C6 alkyl group, a halogen atom, a hydroxyl group, or a C1 to C6 alkoxy group; n is a number of 0 or 1; 
R* predstavlja C1 do C6 alkil skupinu (alkilna skupina može po izboru biti supstituirana s metiltio, ili benziloksi skupinom), fenilnom skupinom, alkilnom skupinom fenil-C;.4, ili indolil-C; alkil skupinom (fenilna skupina ili indolilna skupina po izboru su supstituirane s C1 do C6 alkil skupinom, atomom halogena, ili CI do C6 alkoksi skupinom); n je broj 0 ili 1;
The process of claim 2, wherein, in said step b), in case of continuous microwave, mass power density is 1 kilowatt per kilogram of material to 5 kilowatts per kilogram of material; in case of pulse microwave, mass power density is 2 kilowatts per kilogram of material to 10 kilowatts per kilogram of material, the duty ratio is A/B, where A is on-time and B is off-time, and A=1 sec to 100 sec, B=1 sec to 100 sec. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je, u navedenom koraku 2), u slučaju kontinuiranih mikrovalova, masena gustoća snage 1 kW/kg materijala do 5 kW/kg materijala; u slučaju impulsa mikrovalova, masena gustoća snage je 2 kW/kg materijala do 10 kW/kg materijala, a koeficijent ispunjenosti je A/B, gdje A = 1 sekundi do 100 sekundi, B = 1 sekundi do 100 sekundi.
The isolated antigen binding protein of item 9, wherein the reference antibody comprises a heavy chain and a light chain defined by one of the following pairs of sequences: 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema patentnom zahtjevu 1, naznačeno time što referentno protutijelo sadrži teški lanac i lagani lanac definiran jednim od sljedećih parova sekvenci:
The process of claim 39, wherein the dosage form comprises from about 0.5 mg to about 1250 mg of hydrocodone bitartrate or from about 1 mg to 100 mg hydromorphone hydrochloride, or at least about 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg of hydrocodone bitartrate or at least about 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg of hydromorphone hydrochloride. 
HR P20150835 T1 Postupak prema zahtjevu 39, naznačen time da oblik doziranja sadrži od oko 0.5 mg do oko 1250 mg hidrokodon bitartrata ili od oko 1 mg do 100 mg hidromorfon hidroklorida, ili najmanje oko 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, ili 80 mg, 90 mg, 120 mg ili 160 mg hidrokodon bitartrata ili najmanje oko 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg ili 64 mg hidromorfon hidroklorida.
15.4, 16.7, 21.5 and 30.7 degrees 2theta± 0.2 degrees 2theta. The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 8, which is polymorph 4 and has at least reflections in an X-ray powder diffractogram using CuKa1 radiation at 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 8, naznačen time da je polimorf 4 i ima refleksije u difraktogramu X-zraka na prahu korištenjem CuKa, zračenja barem kod 15.4, 16.7, 16.9, 21.5, 224, 1 30.7 stupnjeva 2theta + 0.2 stupnjeva 2theta.
The method for preparing the nonwoven material of claim 21, wherein sufficient nitrogenous base is added to raise the pH to be in the range of about 2.5 to about 6.5. 
Postupak priprave netkanih materijala iz zahtjeva 18, naznačen time, da se dodaje dovoljno dušične baze, da bi se dosegla pH, u rasponu od 3.0- 4.0.
Use of a compound according to Claim 24, for preparing a pharmaceutical composition for treating neuropathic pain caused by diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia and post-herpetic syndrome. 
HR P20161497 T1 neuropatskih bolova koji su uzrokovani sljedećim stanjima: dijabetes, rak, imunološka deficijencija, ozljeda, ishemija, multipla skleroza, išijas, trigeminalna neuralgija i postherpetični sindrom.
A pharmaceutical composition according to any one of claims 1-28, wherein such single dose form is adapted for oral administration. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-31, naznačena time što je takav pojedinačni dozni oblik prilagođen za oralnu primjenu.
A process according to any one of claims 1 to 11 wherein the resolution agent is added to the mixture of stereoisomeric forms of 6-bromo-a-[2-(dimethylamino)ethyl]-2-methoxy-a-1-naphthalenyl-B-phenyl-3-quinolineethanol as a solution in a suitable solvent. 
Postupak prema bilo kojem od zahtjeva 1 do 11 naznačen time da je sredstvo za razlučivanje dodano u smjesu stereoizomernih oblika 6-bromo-a-[2-(dimetilamino)etil]-2-metoksi-a-1-naftalenil-B-fenil-3-kinolinetanola kao otopina u pogodnom otapalu.
allergies or pseudoallergic diseases, which coincide with inflammatory and/or proliferative processes, 
alergija ili pseudo alergijskih bolesti, koje se poklapaju s upalnim i/ili proliferativnim procesima,
Printing sheet according to claim 26, characterised in that Co, Mn, V, Ce, Fe, Cr, Ni, Rh, Ru, or combinations thereof, preferably present in the pigment in more than 10 ppb up to 10 ppm, possibly in combination with Zr, La, Nd, Al, Bi, Sr, Pb, Ba or combinations thereof, preferably present in the pigment in more than 10 ppb up to 10 ppm or 20 ppm, possibly in combination with Ca, K, Li, Zn and combinations thereof, preferably present in the pigment in more than 10 ppb up to 10 ppm or 20 ppm. 
Upotreba arka za tiskanje prema zahtjevu 32, naznačena time da je Co, Mn, V, Ce, Fe, Cr, Ni, Rh, Ru, ili njihove kombinacije, poželjno prisutan u pigmentu u više od 10 ppb sve do 10 ppm, i/ili u slučaju Ce sve do 20 ppm i/ili u slučaju Fe sve do 100 ppm, moguće u kombinaciji sa Zr, La, Nd, Al, Bi, Sr, Pb, Ba ili njihovim kombinacijama, poželjno prisutan u pigmentu u više od 10 ppb sve do 10 ppm ili 20 ppm, moguće u kombinaciji sa Ca, K, Li, Zn i njihovim kombinacijama, poželjno prisutan u pigmentu u više od 10 ppb sve do 10 ppm ili 20 ppm.
a compound of the formula: or a pharmaceutically acceptable salt thereof; 
Spoj sa formulom: [image] gdje: V je alkil;
adjusting the solution resulting from step (iii) to a protein concentration of 4 to 7%, and a pH value of 5.2 to 7.0; 
podešavanje otopine dobivene u koraku (iii) do koncentracije proteina od 4 do 7% i pH vrijednosti od 5.2 do 7.0;
dividing the portion taken in step a) to obtain a portion of the cell culture conditioned medium not containing cells of the tissue engineered product; 
(b) pripreme dijela kondicioniranog medija stanične kulture, pripremljenog u koraku a), koji ne sadržava stanice produkta preinačenog-tkiva;
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to claim 24, wherein the one or more further therapeutic agents are selected from a chemotherapeutic agent, an antiinflammatory agent, or an immunosuppressive and/or immunomodulatory agent. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema zahtjevu 22, naznačen time, što je jedno ili više dodatnih terapeutskih sredstava odabrano iz kemoterapijskog sredstva, protuupalnog sredstva ili imunosupresiva i/ili imunomodulatora.
A process as in Claim 2, wherein the compound of formula (IX-S) is present in an amount of about 1.5 molar equivalents. 
Postupak kao u Zahtjevu 2, pri čemu spoj formule (IX-S) je prisutan u količini od oko 1.5 molarna ekvivalenta.
Figures 2 and 3 show a pH-independent in vitro release characteristic in the range from pH 1 to 7.5 in case carbopol® is not present and a ph-dependent release characteristic wherein the release characteristic in the range of pH < 4.5 is faster in case carbopol® is present. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da rezultirajuća tableta osigurava pH-ovisno oslobađanje karakterizirano bržim oslobađanjem karakterističnim u rasponu pH < 4.5, te sporijim i nadalje pH-neovisnim oslobađanjem karakterističnim u rasponu od pH 4.5 do 7.5.
between 4 and 8 a.m. 
između 4 i 8 sati ujutro.
According to another embodiment of the invention the PDE4 inhibitor is cilomilast. 
Prema sljedećem utjelovljenju predmetnog izuma f2-agonist je salmeterol, osobito salmeterol ksinafoat.
For example compound No. 4 of table 1 shows an IC50 of 0.007 uM and compound No. 4 of table 2 shows an IC50 of 0.006 uM. 
Kao primjer, spoj br. 4 u Tablici 1 pokazuje ICsg od 0,007 mM, a spoj br. 4 u Tablici 2 pokazuje ICso od 0,006 mM. Primjeri formulacija
The resultant solution was washed with water, saturated aqueous NaCl. 
Rezultirajuća otopina je isprana sa vodom, zasićenom vodenom otopinom NaCl.
This causes the hammer member 28 to strike the end of an anvil in the form of a sleeve 34 lining the in-use upper end of the interior of housing 11, thereby imparting an impulse. 
Ovo uzrokuje da dio 28 čekića udari o kraj nakovnja u obliku košuljice 34 koja pri upotrebi oblaže gornji kraj unutrašnjosti kućišta 11, čime predaje impuls.
a double-stranded nucleic acid molecule and drug carrier comprising a mixture of a retinoid and a lipid, wherein the double-stranded nucleic acid molecule comprises the structure (A1): 
(i) dvolančanu molekulu nukleinske kiseline i nosač lijekova, koji sadrži smjesu retinoida 1 lipida, gdje dvolančana molekula nukleinske kiseline ima strukturu (A1):
Compositions for parenteral administration are typically presented as sterile aqueous or oily solutions or fine suspensions, or may be provided in finely divided sterile powder form for making up extemporaneously with sterile water for injection. 
Pripravci za parenteralnu primjenu su obično prisutni kao sterilne vodene ili uljne otopine ili fine suspenzije ili su to fino usitnjeni sterilni prašci za ekstemporalnu pripremu sa sterilnom vodom za injekcije.
is selected from H, optionally substituted C1-C18 alkyl, optionally substituted C6-C12 aryl, optionally substituted hetero C5-C10 aryl, optionally substituted C1-C10 cycloalkyl, and optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
odabran od H, proizvoljno supstituiranog C1-C8 alkil, proizvoljno supstituiranog C6-C12 aril, proizvoljno supstituiranog hetero C5-C10 arila, proizvoljno supstituiranog C3-C10 cikloalkila i proizvoljno supstituiranog hetero C3-C10 cikloalkila, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
Still more advantages compounds have an EC50 value in this assay of less than about 1 uM. 
Još je povoljnije kad spojevi izuma imaju ECs4 vrijednost u tim ispitivanjima manjuod oko 1uM.
The antibody of claim 4, wherein the single chain antibody is a camelid antibody. A humanized antibody variable domain having a functional antigen binding region, said humanized antibody variable domain comprising non-human CDR1-H1, CDR2-H2, CDR3-H3, CDR1-L1, CDR2-L2, and CDR3-L3 having at least 90% homology to CDR1-H1, CDR2-H2, CDR3-H3, CDR1-L1, CDR2-L2, and CDR3-L3 of mAb 3C2-1D12 incorporated into a human antibody variable domain. 
Izolirano monoklonsko protutijelo koje se selektivno veže na ABCB5 naznačeno time da sadrži varijabilnu domenu teškog lanca imunoglobulina koja ima CDR1-H1 koja sadrži aminokiselinsku sekvencu DYYMY, CDR2-H2 koja sadrži aminokiselinsku sekvencu TINDGGTHTY, i CDR3-H3 koja sadrži aminokiselinsku sekvencu DDYYYGSHFDAMDY i varijabilnu domenu lakog lanca imunoglobulina, koja ima CDR1-L1 koja sadrži aminokiselinsku sekvencu RASKSVSTSGYSYMH, CDR2-L2 koja sadrži aminokiselinsku sekvencu LVSNLES, i CDR3-L3 koja sadrži aminokiselinsku sekvencu QHIRELTR.
A combination for use according to claim 9, wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) B2-agonisti i (b) kortikosteroidi.
(viii) chemical symbols have their usual meanings; SI units and symbols are used; 
(viii) kemijski simboli imaju svoja uobičajena značenja, korišten je SI sustav jedinica;
- 0.3 weight percent polysorbate 20; and an aqueous vehicle. 
0,1 - 0,3 težinskih postotaka polisorbata 20; i
The binding compound of .17, wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, and a diabody. 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 1, naznačeno time, što je antitijelo ili antigen-vežući fragment istog, fragment antitijela koji se bira iz grupe koja sadrži Fab, Fab', Fab'-SH, Fv, scFv, F(ab'),, 1 bispecifično antitijelo.
The aqueous pharmaceutical suspension according to claim 7, wherein the buffering uses a buffer system comprising, by weight/volume (g/100mL), about 0.22% to about 0.87% of sodium phosphate monobasic or a corresponding equivalent amount of a sodium phosphate monobasic hydrate; and about 0.32% to about 1.15% of sodium phosphate dibasic or a corresponding equivalent amount of a sodium phosphate dibasic hydrate. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što puferiranje se vrši puferskim sustavom koji sadrži, težinski/volumno (g/100 ml), otprilike 0,22 % do otprilike 0,87 % jednobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu jednobaznog natrijevog fosfata hidrata; i otprilike 0,32 % do otprilike 1,15 % dvobaznog natrijevog fosfata ili odgovarajuću ekvivalentnu količinu dvobaznog natrijevog fosfata hidrata.
an active ingredient consisting of a compound according to any one of items 1-3 or a polymorphic form according to any one of items 4-24, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži: aktivni sastojak koji se sastoji od spoja prema zahtjevu I ili 2 ili polimorfnog oblika prema zahtjevu 3, te farmaceutski prihvatljiv nosač.
A method according to claim 1, said method comprising the administration to a subject in need thereof of a compound selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih:
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 9, wherein said anti-proliferative cytotoxic agent is cisplatin. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 9, gdje navedeni anti-proliferativni citotoksični agens je cisplatin.
A process according to [7], wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio=3:1-5:1) or a mixed solvent of isopropyl alcohol and water (volume ratio=9:1-10:1). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo miješano otapalo s-butil alkohola i vode (omjer volumena = 3:1-5:1) ili miješano otapalo izopropil alkohola i vode (omjer volumena = 9:1- .
The method of claim 24 further comprising: fastening a first floor and/or ceiling truss to an integrated truss portion of the first structural truss panel so that the first floor and/or ceiling truss supports a member comprising a ceiling of a first space defined at least partially by the first structural truss panel and a floor of a second space defined at least partially by the second structural truss panel; and, 
Postupak prema zahtjevu 4, naznačen time da nadalje sadrži: pričvršćivanje prvog rešetkastog nosača poda i/ili stropa na integrirani rešetkasti dio prve konstrukcijske rešetkaste ploče tako da prva rešetka poda i/ili stropa nosi element koji sadrži strop prvog prostora definiranog barem djelomično s prvom strukturnom rešetkastom pločom (20) i pod od drugog prostora definiranog barem djelomično s drugom strukturnom rešetkastom pločom (20); te
Preferably, each of the tagging sequences and/or each of the duplicated sequences integrate at the 5' end of the same CRISPR locus. 
Postupak prema zahtjevu 1, naznačen time da se 5' i/ili 3' završetak barem prve CRISPR razmaknice navedenog
The compound of claim 2, wherein R1 is hydrogen or methyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 vodik ili metil.
Treating the resulting pyrroline of formula A-3 with a strong base to yield pyrrole derivative of formula A-4, in a suitable solvent such as DMF or DMSO, in a presence of base, 
obrade dobivenog pirolina formule A-3 s jakom bazom kako bi se dobilo pirolni derivat formule A-4 u pogodnom otapalu, poput DMF ili DMSO, u prisutnosti baze,